Shanghai OPM Biosciences Hits Day High with 7.6% Intraday Surge

Shanghai OPM Biosciences Co. has experienced a significant uptick in its stock performance, gaining 7.6% on March 6, 2026. The stock reached an intraday high of CNY 49.97, marking a notable moment in its trading activity. This performance stands in contrast to the China Shanghai Composite, which saw a modest increase of 0.38% on the same day. Despite this daily gain, the company has faced challenges over a longer time frame. Over the past week, Shanghai OPM Biosciences has seen a decline of 3.83%, and its one-month performance reflects a decrease of 12.4%. Year-to-date, the stock is nearly flat with a slight decline of 0.06%. However, on a yearly basis, it has managed to generate a return of 15.2%, albeit lower than the China Shanghai Composite's return of 21.98%. The company's market capitalization stands at CNY 5,991 million, placing it in the mid-cap category within the pharmaceuticals and biotechnology industry. Key financial metrics indicate a return on equity of 2.02% and a price-to-book ratio of 2.85, suggesting a fair valuation amidst its recent performance trends.